FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015212522> ?p ?o ?g. }

• W2015212522 endingPage "1408" @default.
• W2015212522 startingPage "1403" @default.
• W2015212522 abstract "Objective To determine whether topically applied ESBA105, a single-chain antibody fragment against tumor necrosis factor (TNF)-α, could efficiently penetrate into the anterior chamber of the human eye. Design Multicenter, interventional cohort study. Participants Otherwise healthy patients undergoing cataract surgery (cohorts I–III) or combined cataract surgery and vitrectomy (cohort IV). Methods ESBA105 (n = 57) or placebo (n = 22) was preoperatively applied as eye drops to 1 eye in patients scheduled for cataract surgery (n = 73) or combined cataract surgery and vitrectomy (n = 6). ESBA105 was administered on the day of surgery at 1-hour intervals (last dose 1 hour preoperatively) as 1.6 mg in 4 drops for cohort I (n = 15) and as 3.2 mg in 8 drops for cohorts II (n = 15) and IV (n = 6). Cohort III (n = 43) was randomized 1:1 in double-masked fashion to receive either ESBA105 6.4 mg or placebo over 4 days using 4 drops per day at 4-hour intervals (last dose 12 hours preoperatively). Aqueous humor (all cohorts), vitreous humor (cohort IV only), and blood samples (all cohorts) were collected for measurement of ESBA105. Main Outcome Measures ESBA105 intraocular concentration. Results Both 4 times daily over 4 days dosing (cohort III) and 8 times daily dosing (cohorts II and IV) resulted in reliably high ESBA105 concentrations in aqueous humor. Mean molar excess of intraocular ESBA105 over its target (intraocular TNF-α) was calculated as 96-fold (cohort III) to 359-fold (cohorts II and IV). Results from the cohorts receiving 4 and 8 hourly drops per 1 day (cohorts I, II, and IV) indicated that dose-dependent intraocular concentrations of ESBA105 were achieved within hours of dosing. After 8 times daily dosing, 5 of 6 vitreous samples (cohort IV) had undetectable ESBA105 levels. ESBA105 was detected in 17 of 55 preoperative serum samples but no longer detectable in serum 1 day after surgery (0 of 19 samples). In cohort III, treatment-emergent adverse events were identical between ESBA105 and placebo groups (2 cases each of eye irritation). Conclusions These results demonstrate that the topically applied single-chain antibody fragment ESBA105 penetrated into the anterior chamber of the human eye at therapeutic levels. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references. To determine whether topically applied ESBA105, a single-chain antibody fragment against tumor necrosis factor (TNF)-α, could efficiently penetrate into the anterior chamber of the human eye. Multicenter, interventional cohort study. Otherwise healthy patients undergoing cataract surgery (cohorts I–III) or combined cataract surgery and vitrectomy (cohort IV). ESBA105 (n = 57) or placebo (n = 22) was preoperatively applied as eye drops to 1 eye in patients scheduled for cataract surgery (n = 73) or combined cataract surgery and vitrectomy (n = 6). ESBA105 was administered on the day of surgery at 1-hour intervals (last dose 1 hour preoperatively) as 1.6 mg in 4 drops for cohort I (n = 15) and as 3.2 mg in 8 drops for cohorts II (n = 15) and IV (n = 6). Cohort III (n = 43) was randomized 1:1 in double-masked fashion to receive either ESBA105 6.4 mg or placebo over 4 days using 4 drops per day at 4-hour intervals (last dose 12 hours preoperatively). Aqueous humor (all cohorts), vitreous humor (cohort IV only), and blood samples (all cohorts) were collected for measurement of ESBA105. ESBA105 intraocular concentration. Both 4 times daily over 4 days dosing (cohort III) and 8 times daily dosing (cohorts II and IV) resulted in reliably high ESBA105 concentrations in aqueous humor. Mean molar excess of intraocular ESBA105 over its target (intraocular TNF-α) was calculated as 96-fold (cohort III) to 359-fold (cohorts II and IV). Results from the cohorts receiving 4 and 8 hourly drops per 1 day (cohorts I, II, and IV) indicated that dose-dependent intraocular concentrations of ESBA105 were achieved within hours of dosing. After 8 times daily dosing, 5 of 6 vitreous samples (cohort IV) had undetectable ESBA105 levels. ESBA105 was detected in 17 of 55 preoperative serum samples but no longer detectable in serum 1 day after surgery (0 of 19 samples). In cohort III, treatment-emergent adverse events were identical between ESBA105 and placebo groups (2 cases each of eye irritation). These results demonstrate that the topically applied single-chain antibody fragment ESBA105 penetrated into the anterior chamber of the human eye at therapeutic levels." @default.
• W2015212522 created "2016-06-24" @default.
• W2015212522 creator A5022956666 @default.
• W2015212522 creator A5028533210 @default.
• W2015212522 creator A5034389433 @default.
• W2015212522 creator A5034853249 @default.
• W2015212522 creator A5038602378 @default.
• W2015212522 creator A5039589556 @default.
• W2015212522 creator A5051442880 @default.
• W2015212522 creator A5074898825 @default.
• W2015212522 creator A5077408843 @default.
• W2015212522 creator A5087697455 @default.
• W2015212522 date "2013-07-01" @default.
• W2015212522 modified "2023-09-25" @default.
• W2015212522 title "Penetration of a Topically Administered Anti–Tumor Necrosis Factor Alpha Antibody Fragment into the Anterior Chamber of the Human Eye" @default.
• W2015212522 cites W1553493356 @default.
• W2015212522 cites W1977672535 @default.
• W2015212522 cites W1981891070 @default.
• W2015212522 cites W1984688297 @default.
• W2015212522 cites W1987917702 @default.
• W2015212522 cites W1990631195 @default.
• W2015212522 cites W1996853317 @default.
• W2015212522 cites W1997103341 @default.
• W2015212522 cites W1997286390 @default.
• W2015212522 cites W2008930614 @default.
• W2015212522 cites W2009811989 @default.
• W2015212522 cites W2015932505 @default.
• W2015212522 cites W2016495793 @default.
• W2015212522 cites W2070623276 @default.
• W2015212522 cites W2081461448 @default.
• W2015212522 cites W209727533 @default.
• W2015212522 cites W2111546909 @default.
• W2015212522 cites W2112079144 @default.
• W2015212522 cites W2154862191 @default.
• W2015212522 cites W2165278803 @default.
• W2015212522 cites W2207822051 @default.
• W2015212522 doi "https://doi.org/10.1016/j.ophtha.2012.12.015" @default.
• W2015212522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23490328" @default.
• W2015212522 hasPublicationYear "2013" @default.
• W2015212522 type Work @default.
• W2015212522 sameAs 2015212522 @default.
• W2015212522 citedByCount "21" @default.
• W2015212522 countsByYear W20152125222014 @default.
• W2015212522 countsByYear W20152125222015 @default.
• W2015212522 countsByYear W20152125222016 @default.
• W2015212522 countsByYear W20152125222018 @default.
• W2015212522 countsByYear W20152125222019 @default.
• W2015212522 countsByYear W20152125222020 @default.
• W2015212522 countsByYear W20152125222022 @default.
• W2015212522 crossrefType "journal-article" @default.
• W2015212522 hasAuthorship W2015212522A5022956666 @default.
• W2015212522 hasAuthorship W2015212522A5028533210 @default.
• W2015212522 hasAuthorship W2015212522A5034389433 @default.
• W2015212522 hasAuthorship W2015212522A5034853249 @default.
• W2015212522 hasAuthorship W2015212522A5038602378 @default.
• W2015212522 hasAuthorship W2015212522A5039589556 @default.
• W2015212522 hasAuthorship W2015212522A5051442880 @default.
• W2015212522 hasAuthorship W2015212522A5074898825 @default.
• W2015212522 hasAuthorship W2015212522A5077408843 @default.
• W2015212522 hasAuthorship W2015212522A5087697455 @default.
• W2015212522 hasConcept C118487528 @default.
• W2015212522 hasConcept C126322002 @default.
• W2015212522 hasConcept C141071460 @default.
• W2015212522 hasConcept C142724271 @default.
• W2015212522 hasConcept C201903717 @default.
• W2015212522 hasConcept C204787440 @default.
• W2015212522 hasConcept C27081682 @default.
• W2015212522 hasConcept C2775888743 @default.
• W2015212522 hasConcept C2777288759 @default.
• W2015212522 hasConcept C2778257484 @default.
• W2015212522 hasConcept C2781242345 @default.
• W2015212522 hasConcept C42219234 @default.
• W2015212522 hasConcept C71924100 @default.
• W2015212522 hasConcept C72563966 @default.
• W2015212522 hasConceptScore W2015212522C118487528 @default.
• W2015212522 hasConceptScore W2015212522C126322002 @default.
• W2015212522 hasConceptScore W2015212522C141071460 @default.
• W2015212522 hasConceptScore W2015212522C142724271 @default.
• W2015212522 hasConceptScore W2015212522C201903717 @default.
• W2015212522 hasConceptScore W2015212522C204787440 @default.
• W2015212522 hasConceptScore W2015212522C27081682 @default.
• W2015212522 hasConceptScore W2015212522C2775888743 @default.
• W2015212522 hasConceptScore W2015212522C2777288759 @default.
• W2015212522 hasConceptScore W2015212522C2778257484 @default.
• W2015212522 hasConceptScore W2015212522C2781242345 @default.
• W2015212522 hasConceptScore W2015212522C42219234 @default.
• W2015212522 hasConceptScore W2015212522C71924100 @default.
• W2015212522 hasConceptScore W2015212522C72563966 @default.
• W2015212522 hasIssue "7" @default.
• W2015212522 hasLocation W20152125221 @default.
• W2015212522 hasLocation W20152125222 @default.
• W2015212522 hasOpenAccess W2015212522 @default.
• W2015212522 hasPrimaryLocation W20152125221 @default.
• W2015212522 hasRelatedWork W2003938723 @default.
• W2015212522 hasRelatedWork W2047967234 @default.
• W2015212522 hasRelatedWork W2081741916 @default.
• W2015212522 hasRelatedWork W2118496982 @default.
• W2015212522 hasRelatedWork W2439875401 @default.

• next